A Phase 3 interventional study of BEMA Fentanyl in Pain and Cancer, sponsored by BioDelivery Sciences International. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-05.
Sponsored by BioDelivery Sciences International · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,884 studies in Pain with a site in United States — 314 open to participants now, 393 under way, 24 of them phase 3. Pain · United States.
Among the 2,884 studies in Pain with a site in United States, this one is the 396th largest by enrollment of the 2,562 interventional ones that give a count, is one of 107 that started in 2006, is one of 343 in phase 3, and was the 199th registered.
10,069 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →314 of the 2,884 studies in Pain with a site in United States are open now. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 30–75
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Columbia University · Sites in United States
Ages 6–17
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
Ambros Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,884 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 249 · Phase 2 416 · Phase 3 375 · Phase 4 372
First in 1957; this study’s year is marked. 107 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 244 is above the median of 66 across 8,507 interventional studies indexed under Pain.
Median enrollment 66 across the 2,562 interventional studies, 99 across the 299 observational. Of the 2,226 that completed or were terminated, 1,051 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
670 of 2,884 have an industry lead sponsor. The 10 most frequent:
BioDelivery Sciences International is the lead sponsor of 21 studies on the registry; 1 is open to participants now.
BioDelivery Sciences International has 9 studies filed under Pain — fewer than ten, so there is no comparison to draw.
172 of the studies in Pain with a site in United States that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05000281Phase 3Major Extremity Trauma Research ConsortiumEffect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures | 2026-11-30 |
| NCT07226258Phase 3Saol Therapeutics IncPhase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | 2026-11-30 |
| NCT05964868Phase 3Jessyka LighthallEfficacy of Liposomal Bupivacaine Post Septorhinoplasty | 2026-12 |
| NCT07832552Phase 3Harrow IncA Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery | 2026-12 |
| NCT03823534Phase 3St. Louis UniversityPost-Op Pain Control for Prophylactic Intramedullary Nailing. | 2026-12-31 |
Add all 172 to your calendar (.ics) → With an account.
Among the 2,884 studies in Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety of BEMA fentanyl at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy. The standard of care for these breakthrough pain episodes is a rapid onset, short acting analgesic with minimal associated sleepiness. Oral morphine, oxycodone and hydromorphone are routinely used, but because of slow and variable oral absorption, the pain control is not the best with these products. Oral transmucosal fentanyl citrate (OTFC) has been used successfully in treating breakthrough pain episodes associated with cancer. OTFC is a lozenge of fentanyl on a stick and is administered by continuously swabbing the interior of the subject's mouth until the product is dissolved (approximately 15 to 30 minutes). The buccal route of administration avoids the delay and variability associated with oral absorption.
BioDelivery Sciences International, Inc. (BDSI) has developed BEMA (BioErodible MucoAdhesive) fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small disc that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the disc readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the disc are water soluble, so the entire dosage form dissolves within 30 minutes of application.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BEMA Fentanyl
Drug: BEMA Fentanyl
buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
Also known as: bioerodible mucoadhesive system
Percentage of Participants With Adverse Events.
After the first dose of BEMA Fentanyl, all adverse events were recorded and summarized.
Time frame: Participants were followed for the duration of the study, an average of 126 days
The enrollment period was 3/14/06 - 6/13/08. Subjects were recruited from academic \& private clinics in the US. Two groups of subjects were eligible for enrollment in this study. Subjects were eligible to enter this study following completion of the placebo-controlled study, FEN-201 or they were enrolled directly into this study.
| Milestone | Open Label Fentanyl Treatment |
|---|---|
| Started | 244 |
| Completed | 82 |
| Not completed | 162 |
| Withdrew: Withdrawal by subject | 34 |
| Withdrew: Adverse event | 30 |
| Withdrew: Death | 32 |
| Withdrew: Lack of efficacy | 12 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Protocol violation | 6 |
| Withdrew: Physician decision | 21 |
| Withdrew: Other reason | 22 |
| Withdrew: No dose taken | 1 |
After the first dose of BEMA Fentanyl, all adverse events were recorded and summarized.
| percentage of participants | Open Label Fentanyl Treatment |
|---|---|
| Percentage of Participants With Adverse Events. | 88.5 |
Collected over The duration of a subject's particpation in the trial.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Label Fentanyl Treatment | — | 121/243 (49.8%) | 215/243 (88.5%) |
| Event | Open Label Fentanyl Treatment |
|---|---|
| Disease progressionGeneral disorders | 27/243 |
| PneumoniaInfections and infestations | 17/243 |
| Deep vein thrombosisVascular disorders | 6/243 |
| SepsisInfections and infestations | 5/243 |
| anemiaBlood and lymphatic system disorders | 3/243 |
| DysphagiaGastrointestinal disorders | 3/243 |
| CellulitisInfections and infestations | 3/243 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/243 |
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/243 |
| Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/243 |
| Event | Open Label Fentanyl Treatment |
|---|---|
| NauseaGastrointestinal disorders | 74/243 |
| VomitingGastrointestinal disorders | 52/243 |
| DizzinessNervous system disorders | 35/243 |
| AnemiaBlood and lymphatic system disorders | 31/243 |
| Edema peripheralGeneral disorders | 29/243 |
| DehydrationMetabolism and nutrition disorders | 29/243 |
| Disease progressionGeneral disorders | 28/243 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 28/243 |
| ConstipationGastrointestinal disorders | 26/243 |
| AstheniaGeneral disorders | 25/243 |
| Age, Categorical(Participants) | Open Label Fentanyl Treatment |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 168 |
| >=65 years | 75 |
| Age Continuous(years) | Open Label Fentanyl Treatment |
|---|---|
| Mean | 58.0 ± 12.12 |
| Sex: Female, Male(Participants) | Open Label Fentanyl Treatment |
|---|---|
| Female | 128 |
| Male | 115 |
| Race (NIH/OMB)(Participants) | Open Label Fentanyl Treatment |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 23 |
| White | 209 |
| More than one race | 0 |
| Unknown or Not Reported | 9 |
| Region of Enrollment(participants) | Open Label Fentanyl Treatment |
|---|---|
| United States | 243 |
The record gives a start of Feb 2006, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fentanyl Buccal Soluble Film
BioDelivery Sciences International